Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levomepromazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 6/20 | 1.00 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.51 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 7/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 6/20 | 1.00 |
| ▸ | HTR1A | P08908 | 6/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 6/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 6/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 5/20 | 1.00 |
| ▸ | DRD1 | P21728 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 4/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.74 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levomepromazine SCHEMBL29425180 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Dextromepromazine SCHEMBL30411640 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL29384983 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL29508092 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL8762418 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Dextromepromazine SCHEMBL23859840 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL6944555 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL418079 | 0.99 | CYP2D6 (0.98) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL29846205 | 0.99 | CYP2D6 (0.98) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL1611636 | 0.99 | CYP2D6 (0.98) | CYP2D6CHRM2HTR1ACHRM1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8459 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| US-20260034065-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2026-02-05 | — | — | US | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| US-12527754-B2 | Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions | TUFTS MEDICAL CENTER, INC. (US) | 2026-01-20 | — | — | US | claimed |
| EP-4674482-A2 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE CONTAINING BREXPIPRAZOLE OR SALT THEREOF | Otsuka Pharmaceutical Co., Ltd. (JP) | 2026-01-07 | — | — | EP | claimed |
| US-20250367212-A1 | PHARMACOTHERAPY FOR OBSESSIVE-COMPULSIVE DISORDER TARGETING DOPAMINE D1 SIGNAL IN STRIATAL STRIOSOMES | MATSUMOTO SHINICHI (JP) | 2025-12-04 | — | — | US | claimed |
| EP-4654963-A1 | TREATMENT OF MENTAL ILLNESS VIA ADMINISTRATION OF BUNTANETAP AND ANALOGUES THEREOF | Annovis Bio, Inc. (US) | 2025-12-03 | — | — | EP | claimed |
| US-12472146-B2 | Extended release pharmaceutical formulation | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2025-11-18 | — | — | US | claimed |
| US-20250295671-A1 | Hazardous Agent Injection System | ANTARES PHARMA, INC. (US) | 2025-09-25 | — | — | US | claimed |
| WO-1997035584-A1 | METHOD FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1997-10-02 | — | — | WO | claimed |
| US-5585243-A | SEPARATELY INCUBATING HUMAN PLATELETS WITH BLOOD SAMPLE ANDREAGENT DRUG SOLUTION TO FORM COMPLEXES, DETERMINING AMOUNT OF BOUND ANTIBODY | THE BLOOD CENTER OF SOUTHEASTERN WISCONSIN, INC. (US) | 1996-12-17 | — | — | US | claimed |
| WO-1996033721-A1 | ANTI-EMETIC PHARMACEUTICAL COMPOSITIONS CONTAINING METHOTRIMEPRAZINE | LINK PHARMACEUTICALS LIMITED (GB) | 1996-10-31 | — | — | WO | claimed |
| WO-1996001631-A1 | NOVEL COMBINATION PRODUCT COMPRISING CAPRIPRAMINE AND A NEUROLEPTIC | PIERRE FABRE MEDICAMENT (FR) | 1996-01-25 | — | — | WO | claimed |
| WO-1995008116-A1 | METHOD OF DETECTING CYTOPENIA THAT IS MEDIATED BY DRUG-DEPENDENT ANTIBODY BINDING TO BLOOD CELLS | THE BLOOD CENTER OF SOUTHEASTERN WISCONSIN, INC. (US) | 1995-03-23 | — | — | WO | claimed |
| US-5192552-A | Capsules coated with ethyl cellulose and sulfosuccinate in cyclohexane | EGIS GYOGYSZERGYAR (HU) | 1993-03-09 | — | — | US | claimed |
| EP-0180364-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PHENOTHIAZINES | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1990-03-07 | — | — | EP | claimed |
| EP-0251904-B1 | PROCESS FOR THE PREPARATION OF ACIDIC LEVOMEPROMAZINE MALEATE | RHONE-POULENC SANTE (FR) | 1990-01-10 | — | — | EP | claimed |
| EP-0174342-B1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1989-12-20 | — | — | EP | claimed |
| EP-0251904-A1 | Process for the preparation of acidic levomepromazine maleate | RHONE-POULENC SANTE (FR) | 1988-01-07 | — | — | EP | claimed |